The makers of Xarelto wanted the FDA to approve a claim that Xarelto was more effective than Coumadin — a blood thinner used for more than 50 years — at preventing blood clots and stroke. The agency declined. Xarelto will carry a safety warning stating that patients should not stop taking the drug without notifying their physicians, as discontinuing the drug can increase the risk of stroke.
Related Articles on FDA Approvals:
FDA Reports Increase in New Drug Approvals in FY 2011
FDA Approval for Edwards’ Sapien Device is a First for U.S. Market
FDA: Medtronic Catheter Effective, But Doesn’t Meet Safety Goals
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
